@entity5505 versus XXXX plus @entity4967 in the treatment of soft-tissue infections.

@entity1 @entity6081 @entity2890 @entity6 @entity2688 @entity794 @entity102 @entity4967 @entity5505
Case report forms from a multicenter, randomized trial comparing @entity5505 (50 @entity1 ) with @entity2890 plus @entity4967 (control group, 44 @entity1 ) in the treatment of skin and soft-tissue infections were reviewed. Two subsets of @entity1 were identified. The target @entity1 population (group I) comprised older @entity1 with predisposing @entity102 (eg, @entity6 ) and an average of 1.8 bacterial pathogens per @entity1 . Necrotizing soft-tissue and @entity6081 predominated. Group II comprised younger @entity1 with acute onset of monomicrobial @entity2688 or staphylococcal or streptococcal abscess. Clinical cure or improvement was achieved in 93% of @entity5505 -treated and 94% of control group I @entity1 . Bacteriological eradication of the initial pathogens without superinfection was obtained in 85% and 82%, respectively, of the two treatment groups. In group II, each of the nine @entity5505 -treated @entity1 was cured or improved and bacteria were eradicated; in the control group, nine of ten @entity1 were clinically and bacteriologically cured. Among all @entity1 , @entity794 was eradicated in 18 of 19 treated with @entity5505 and in 14 of 15 treated with the control agents. The results of the study demonstrate the efficacy of @entity5505 as initial monotherapy for soft-tissue infections in @entity1 with compromised vascularity.
